Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) FCF Margin (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed FCF Margin for 11 consecutive years, with 6669.13% as the latest value for Q3 2025.

  • On a quarterly basis, FCF Margin rose 455492.0% to 6669.13% in Q3 2025 year-over-year; TTM through Dec 2025 was 19848.75%, a 1978533.0% decrease, with the full-year FY2025 number at 19848.75%, down 1978468.0% from a year prior.
  • FCF Margin was 6669.13% for Q3 2025 at Cartesian Therapeutics, up from 5749.66% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 6669.13% in Q3 2025 to a low of 6045.75% in Q1 2025.
  • A 5-year average of 241.05% and a median of 69.79% in 2022 define the central range for FCF Margin.
  • Biggest YoY gain for FCF Margin was 455492bps in 2025; the steepest drop was -576289bps in 2025.
  • Cartesian Therapeutics' FCF Margin stood at 108.65% in 2021, then surged by 36bps to 69.79% in 2022, then crashed by -305bps to 282.48% in 2023, then surged by 77bps to 64.47% in 2024, then surged by 10444bps to 6669.13% in 2025.
  • Per Business Quant, the three most recent readings for RNAC's FCF Margin are 6669.13% (Q3 2025), 5749.66% (Q2 2025), and 6045.75% (Q1 2025).